VANCOUVER, British Columbia, Dec. 13, 2010 (GLOBE NEWSWIRE) -- biOasis Technologies Inc. (TSX-V:BTI) announced today the completion of the development and initial testing of a second method to detect levels of a serum protein (p97) that is reported to be associated with Alzheimer's disease (AD). The project, which was initiated and announced in late 2008, was intended to develop a SISCAPA (Stable Isotope Standards and Capture by Anti-Peptide Antibodies) assay capable of detecting and measuring protein levels in human plasma.
BiOasis Announces Completion Of Mass Spectrometry Method Intended To Assist With In Vitro Diagnosis Of Alzheimer's Disease
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.